Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA127 in post-ischemic stroke
NCT06135103Phase 2Recruiting
- Sponsor
- Constant Therapeutics LLC
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing talfirastide (TXA127) with placebo (2 arms). Primary endpoint: Fugl-Meyer Assessment of Upper Extremity at 12 weeks. Started Nov 2023; status: recruiting.
02
Drugs
talfirastide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06135103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135103.